Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + empagliflozin + sitagliptin
- Development stage
- Unknown
- Lead developer
- Bahria University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This triple combination therapy, consisting of metformin, empagliflozin, and sitagliptin, is being evaluated by Bahria University for the treatment of type 2 diabetes mellitus. The combination leverages three distinct mechanisms of action: metformin (a biguanide) reduces hepatic glucose production and improves insulin sensitivity; empagliflozin (an SGLT2 inhibitor) promotes the renal excretion of glucose; and sitagliptin (a DPP-4 inhibitor) enhances the incretin effect to stimulate insulin secretion and suppress glucagon release. It is currently being studied in a Phase 4, randomized, open-label clinical trial in Pakistan to compare its efficacy and safety as an initial triple therapy against other combinations in newly diagnosed, treatment-naive patients.
- Other names
- Metformin-Empagliflozin-SitagliptinMetformin + Empagliflozin + Sitagliptin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on metformin + empagliflozin + sitagliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + empagliflozin + sitagliptin.